Normal hematopoietic stem cells within the AML bone marrow have a distinct and higher ALDH activity level than co-existing leukemic stem cells.

Persistence of leukemic stem cells (LSC) after chemotherapy is thought to be responsible for relapse and prevents the curative treatment of acute myeloid leukemia (AML) patients. LSC and normal hematopoietic stem cells (HSC) share many characteristics and co-exist in the bone marrow of AML patients....

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Gerrit J Schuurhuis, Michael H Meel, Floris Wouters, Lisa A Min, Monique Terwijn, Nick A de Jonge, Angele Kelder, Alexander N Snel, Sonja Zweegman, Gert J Ossenkoppele, Linda Smit
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2013
Materias:
R
Q
Acceso en línea:https://doaj.org/article/afdfbec2f3a140adb7a2c8c49ec3e1ce
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:afdfbec2f3a140adb7a2c8c49ec3e1ce
record_format dspace
spelling oai:doaj.org-article:afdfbec2f3a140adb7a2c8c49ec3e1ce2021-11-18T08:47:30ZNormal hematopoietic stem cells within the AML bone marrow have a distinct and higher ALDH activity level than co-existing leukemic stem cells.1932-620310.1371/journal.pone.0078897https://doaj.org/article/afdfbec2f3a140adb7a2c8c49ec3e1ce2013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24244383/?tool=EBIhttps://doaj.org/toc/1932-6203Persistence of leukemic stem cells (LSC) after chemotherapy is thought to be responsible for relapse and prevents the curative treatment of acute myeloid leukemia (AML) patients. LSC and normal hematopoietic stem cells (HSC) share many characteristics and co-exist in the bone marrow of AML patients. For the development of successful LSC-targeted therapy, enabling eradication of LSC while sparing HSC, the identification of differences between LSC and HSC residing within the AML bone marrow is crucial. For identification of these LSC targets, as well as for AML LSC characterization, discrimination between LSC and HSC within the AML bone marrow is imperative. Here we show that normal CD34+CD38- HSC present in AML bone marrow, identified by their lack of aberrant immunophenotypic and molecular marker expression and low scatter properties, are a distinct sub-population of cells with high ALDH activity (ALDH(bright)). The ALDH(bright) compartment contains, besides normal HSC, more differentiated, normal CD34+CD38+ progenitors. Furthermore, we show that in CD34-negative AML, containing solely normal CD34+ cells, LSC are CD34- and ALDH(low). In CD34-positive AML, LSC are also ALDH(low) but can be either CD34+ or CD34-. In conclusion, although malignant AML blasts have varying ALDH activity, a common feature of all AML cases is that LSC have lower ALDH activity than the CD34+CD38- HSC that co-exist with these LSC in the AML bone marrow. Our findings form the basis for combined functionally and immunophenotypically based identification and purification of LSC and HSC within the AML bone marrow, aiming at development of highly specific anti-LSC therapy.Gerrit J SchuurhuisMichael H MeelFloris WoutersLisa A MinMonique TerwijnNick A de JongeAngele KelderAlexander N SnelSonja ZweegmanGert J OssenkoppeleLinda SmitPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 11, p e78897 (2013)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Gerrit J Schuurhuis
Michael H Meel
Floris Wouters
Lisa A Min
Monique Terwijn
Nick A de Jonge
Angele Kelder
Alexander N Snel
Sonja Zweegman
Gert J Ossenkoppele
Linda Smit
Normal hematopoietic stem cells within the AML bone marrow have a distinct and higher ALDH activity level than co-existing leukemic stem cells.
description Persistence of leukemic stem cells (LSC) after chemotherapy is thought to be responsible for relapse and prevents the curative treatment of acute myeloid leukemia (AML) patients. LSC and normal hematopoietic stem cells (HSC) share many characteristics and co-exist in the bone marrow of AML patients. For the development of successful LSC-targeted therapy, enabling eradication of LSC while sparing HSC, the identification of differences between LSC and HSC residing within the AML bone marrow is crucial. For identification of these LSC targets, as well as for AML LSC characterization, discrimination between LSC and HSC within the AML bone marrow is imperative. Here we show that normal CD34+CD38- HSC present in AML bone marrow, identified by their lack of aberrant immunophenotypic and molecular marker expression and low scatter properties, are a distinct sub-population of cells with high ALDH activity (ALDH(bright)). The ALDH(bright) compartment contains, besides normal HSC, more differentiated, normal CD34+CD38+ progenitors. Furthermore, we show that in CD34-negative AML, containing solely normal CD34+ cells, LSC are CD34- and ALDH(low). In CD34-positive AML, LSC are also ALDH(low) but can be either CD34+ or CD34-. In conclusion, although malignant AML blasts have varying ALDH activity, a common feature of all AML cases is that LSC have lower ALDH activity than the CD34+CD38- HSC that co-exist with these LSC in the AML bone marrow. Our findings form the basis for combined functionally and immunophenotypically based identification and purification of LSC and HSC within the AML bone marrow, aiming at development of highly specific anti-LSC therapy.
format article
author Gerrit J Schuurhuis
Michael H Meel
Floris Wouters
Lisa A Min
Monique Terwijn
Nick A de Jonge
Angele Kelder
Alexander N Snel
Sonja Zweegman
Gert J Ossenkoppele
Linda Smit
author_facet Gerrit J Schuurhuis
Michael H Meel
Floris Wouters
Lisa A Min
Monique Terwijn
Nick A de Jonge
Angele Kelder
Alexander N Snel
Sonja Zweegman
Gert J Ossenkoppele
Linda Smit
author_sort Gerrit J Schuurhuis
title Normal hematopoietic stem cells within the AML bone marrow have a distinct and higher ALDH activity level than co-existing leukemic stem cells.
title_short Normal hematopoietic stem cells within the AML bone marrow have a distinct and higher ALDH activity level than co-existing leukemic stem cells.
title_full Normal hematopoietic stem cells within the AML bone marrow have a distinct and higher ALDH activity level than co-existing leukemic stem cells.
title_fullStr Normal hematopoietic stem cells within the AML bone marrow have a distinct and higher ALDH activity level than co-existing leukemic stem cells.
title_full_unstemmed Normal hematopoietic stem cells within the AML bone marrow have a distinct and higher ALDH activity level than co-existing leukemic stem cells.
title_sort normal hematopoietic stem cells within the aml bone marrow have a distinct and higher aldh activity level than co-existing leukemic stem cells.
publisher Public Library of Science (PLoS)
publishDate 2013
url https://doaj.org/article/afdfbec2f3a140adb7a2c8c49ec3e1ce
work_keys_str_mv AT gerritjschuurhuis normalhematopoieticstemcellswithintheamlbonemarrowhaveadistinctandhigheraldhactivitylevelthancoexistingleukemicstemcells
AT michaelhmeel normalhematopoieticstemcellswithintheamlbonemarrowhaveadistinctandhigheraldhactivitylevelthancoexistingleukemicstemcells
AT floriswouters normalhematopoieticstemcellswithintheamlbonemarrowhaveadistinctandhigheraldhactivitylevelthancoexistingleukemicstemcells
AT lisaamin normalhematopoieticstemcellswithintheamlbonemarrowhaveadistinctandhigheraldhactivitylevelthancoexistingleukemicstemcells
AT moniqueterwijn normalhematopoieticstemcellswithintheamlbonemarrowhaveadistinctandhigheraldhactivitylevelthancoexistingleukemicstemcells
AT nickadejonge normalhematopoieticstemcellswithintheamlbonemarrowhaveadistinctandhigheraldhactivitylevelthancoexistingleukemicstemcells
AT angelekelder normalhematopoieticstemcellswithintheamlbonemarrowhaveadistinctandhigheraldhactivitylevelthancoexistingleukemicstemcells
AT alexandernsnel normalhematopoieticstemcellswithintheamlbonemarrowhaveadistinctandhigheraldhactivitylevelthancoexistingleukemicstemcells
AT sonjazweegman normalhematopoieticstemcellswithintheamlbonemarrowhaveadistinctandhigheraldhactivitylevelthancoexistingleukemicstemcells
AT gertjossenkoppele normalhematopoieticstemcellswithintheamlbonemarrowhaveadistinctandhigheraldhactivitylevelthancoexistingleukemicstemcells
AT lindasmit normalhematopoieticstemcellswithintheamlbonemarrowhaveadistinctandhigheraldhactivitylevelthancoexistingleukemicstemcells
_version_ 1718421343665389568